Dashboard
Manage Tickers

PCVXVaxcyte, Inc.

Nasdaq vaxcyte.com


$ 116.52 $ -0.21 (-0.18 %)    

Wednesday, 18-Sep-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 116.54
$ 116.65
$ 116.40 x 100
$ 116.56 x 100
$ 114.93 - $ 118.50
$ 44.20 - $ 119.50
606,434
na
13.01B
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-29-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-12-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mizuho-maintains-outperform-on-vaxcyte-raises-price-target-to-163
Mizuho Maintains Outperform on Vaxcyte, Ra...
09/10/2024 13:42:28

Mizuho analyst Salim Syed maintains Vaxcyte (NASDAQ:PCVX) with a Outperform and raises the price target from $113 to $163.

reported-earlier-vaxcyte-prices-13b-public-offering-of-10194175-common-shares-and-pre-funded-warrants-at-103share
Reported Earlier, Vaxcyte Prices $1.3B Pub...
09/05/2024 06:30:19

Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in th...

b-of-a-securities-maintains-buy-on-vaxcyte-raises-price-target-to-140
B of A Securities Maintains Buy on Vaxcyte...
09/04/2024 11:34:15

B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $101 to...

jefferies-maintains-buy-on-vaxcyte-raises-price-target-to-129
Jefferies Maintains Buy on Vaxcyte, Raises...
09/03/2024 21:24:26

Jefferies analyst Roger Song maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $108 to $129.

vaxcyte-announces-commences-1b-proposed-public-offering-of-common-stock-and-pre-funded-warrants
Vaxcyte Announces Commences $1B Proposed P...
09/03/2024 20:03:03

why-recursion-pharmaceuticals-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Recursion Pharmaceuticals Shares Are T...
09/03/2024 17:41:09

needham-maintains-buy-on-vaxcyte-raises-price-target-to-140
Needham Maintains Buy on Vaxcyte, Raises P...
09/03/2024 17:32:40

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $95 to $140.

btig-maintains-buy-on-vaxcyte-raises-price-target-to-160
BTIG Maintains Buy on Vaxcyte, Raises Pric...
09/03/2024 17:24:24

BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $98 to $160.

vaxcyte-shoals-technologies-polestar-automotive-applied-optoelectronics-and-other-big-stocks-moving-higher-on-tuesday
Vaxcyte, Shoals Technologies, Polestar Aut...
09/03/2024 14:47:56

bacterial-infections-vaccine-developer-vaxcytes-pneumococcal-shot-shows-promise-in-mid-stage-trial-stock-shoots-higher
Bacterial Infections Vaccine Developer Vax...
09/03/2024 13:40:49

Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candi...

Core News & Articles
Market-Moving News for September 3rd
09/03/2024 12:27:16

AUUD: 78% | Auddia shares are trading higher after the company announced it recently launched both Apple CarPlay and Android Au...

vaxcyte-announced-topline-results-from-phase-12-study-of-vax-31-the-companys-31-valent-pneumococcal-conjugate-vaccine-candidate-at-all-doses-vax-31-demonstrated-robust-opsonophagocytic-activity-immune-responses-for-all-31-serotypes
Vaxcyte Announced Topline Results From Pha...
09/03/2024 11:12:25

At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 SerotypesAt All Doses Studied, V...

peering-into-vaxcytes-recent-short-interest
Peering Into Vaxcyte's Recent Short Interest
08/27/2024 13:15:24

needham-reiterates-buy-on-vaxcyte-maintains-95-price-target
Needham Reiterates Buy on Vaxcyte, Maintai...
08/07/2024 09:41:44

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $95 price target.

vaxcyte-q2-eps-110-misses-098-estimate
Vaxcyte Q2 EPS $(1.10) Misses $(0.98) Esti...
08/06/2024 21:05:47

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.98) by ...

needham-reiterates-buy-on-vaxcyte-maintains-95-price-target
Needham Reiterates Buy on Vaxcyte, Maintai...
06/28/2024 10:18:14

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $95 price target.

cantor-fitzgerald-reiterates-overweight-on-vaxcyte
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:45:17

Cantor Fitzgerald analyst Louise Chen reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight.

cantor-fitzgerald-reiterates-overweight-on-vaxcyte
Cantor Fitzgerald Reiterates Overweight on...
05/09/2024 15:14:41

Cantor Fitzgerald analyst Louise Chen reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight.

needham-reiterates-buy-on-vaxcyte-maintains-95-price-target
Needham Reiterates Buy on Vaxcyte, Maintai...
05/09/2024 10:43:59

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $95 price target.

vaxcyte-q1-eps-085-beats-109-estimate
Vaxcyte Q1 EPS $(0.85) Beats $(1.09) Estimate
05/08/2024 21:26:30

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.09) by 22...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION